Single Arm Clinical Trial of Small Molecule Natural Flavonoid Compounds for Intervention in Neurodegenerative Diseases

Not Applicable

Not yet recruiting

• Conditions: Neurodegenerative Diseases
• Interventions: Drug: SMARTO ONE

• Registration Number: NCT05947409
• Lead Sponsor: Mei Han

Brief Summary

1. Explore the effects of natural plant flavonoids on the positive intervention mechanism of neurotransmitter transmission physiological indicators changes (EEG) in the brain of the study subjects;

2. Investigate the effects of natural plant flavonoids in positively intervening clinical symptoms of the study subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-06-21
• Study First Submitted QC: 2023-07-14
• Study First Posted: 2023-07-17
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-08
• Last Update Posted: 2023-08-14
• Study Start: 2023-08-15
• Primary Completion: 2024-06-15
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age: 25-70 years
2. Patients complaining of sleep disorders, mood disorders (unstable mood, irritability, depression and anxiety) and cognitive decline (people with memory, decreased reaction time, BPSD symptoms) within one month
3. Montreal Cognitive Assessment Scale (MOCA) score ≤26; if MOCA score is not satisfied, then Pittsburgh Sleep Quality Index (PSQI) score >10 and Hamilton Anxiety Scale (HAMA) score >14 or Hamilton Depression Scale (HAMD) score ≥8 are required
4. Patients who can understand and communicate in language, and complete aphasia patients are not included;
5. Patients who agree to participate in this clinical observation and sign the informed consent form.

Exclusion Criteria

1. Patients with severe organ diseases such as heart, kidney, and liver failure, chronic lung diseases such as COPD, and severe diabetes;
2. Patients with severe uncontrolled hypertension;
3. Patients who have taken antipsychotic drugs within the past two weeks;
4. Patients with the core features of Lewy body dementia or significant behavioral variant frontotemporal dementia;
5. Patients with various malignant tumors;
6. Patients with progressive stroke, transient ischemic attack, cerebral hemorrhage after cerebral infarction, and cerebral arteritis;
7. Patients with brain tumors, brain trauma, cerebral parasitic diseases, and other conditions;
8. Pregnant or lactating women;
9. Patients allergic to the known ingredients used in this trial;
10. Patients with active ulcers or bleeding tendencies;
11. Patients with neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis, and Pick's disease;
12. Other patients who are deemed unsuitable to participate in this trial by the investigators.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SMARTO ONE	SMARTO ONE	-

Primary Outcome Measures

Name	Time	Method
Montreal Cognitive Assessment (MoCA)	4 weeks	This outcome measure assesses cognitive ability and memory, with evaluation based on a scoring system.The total score ranges from 0 to 30 points, with scores lower than 26 indicating the presence of cognitive impairment. The lower the score, the more severe the disease.
Hamilton Anxiety Rating Scale (HAMA)	4 weeks	The evaluation criteria for this outcome measure are as follows: 0-6 points indicate no anxiety symptoms; 7-14 points indicate possible anxiety; 15-21 points indicate definite anxiety; 22-29 points indicate significant anxiety; and scores exceeding 29 points suggest severe anxiety.
Pittsburgh Sleep Quality Index (PSQI)	4 weeks	The evaluation criteria for this outcome measure are as follows: 0-5 points indicate very good sleep quality; 6-10 points indicate average sleep quality; 11-15 points indicate poor sleep quality; 16-21 points indicate very poor sleep quality.
Hamilton Depression Scale(HAMD)	4 weeks	The evaluation criteria for this outcome measure are as follows:a score of less than 8 is normal, a score of 8-20 may indicate depression, a score of 21-35 may indicate depression, and a score of more than 35 may not indicate severe depression

Secondary Outcome Measures

Name	Time	Method
Heart rate	baseline, 4 weeks	This is a safety outcome.
Number of breaths in 1 min	baseline, 4 weeks	This is a safety outcome.
Abnormality rate of routine blood tests	baseline, 4 weeks	This is a safety outcome. Included in the outcome indicators are red blood cell count (WBC), haemoglobin concentration (Hb), white blood cell count (WBC), neutrophil count (Neut), lymphocyte count (Lymph), monocyte count (Mono), eosinophil count (Eos), basophil count (Baso) and platelet count (PLT). The abnormal blood count rate was obtained by dividing the number of people with abnormal blood counts by the total number of people with abnormal blood counts.
Liver function-Total Protein(TP)	baseline, 4 weeks	This is a safety outcome.
Electrocardiogram	baseline, 4 weeks	This is a safety outcome.This outcome measure primarily observes ST segment changes to evaluate the presence or improvement of myocardial ischemia.
Blood pressure-Systolic blood pressure(mmHg)	baseline, 4 weeks	This is a safety outcome.
Numerry of participating with adverse events	baseline, 4 weeks	This is a safety outcome.
Adverse event occurrence rate	baseline, 4 weeks	This is a safety outcome.
Body temperature	baseline, 4 weeks	This is a safety outcome.
Liver function-Alanine aminotransferase#ALT#	baseline, 4 weeks	This is a safety outcome.
Liver function-Aspartate aminotransferase (AST)	baseline, 4 weeks	This is a safety outcome.
Blood pressure-Diastolic blood pressure(mmHg)	baseline, 4 weeks	This is a safety outcome.